The main trial, recently published in the New England Journal of Medicine, showed a relevant decrease in severe adverse events in the limbs after angioplasty with MagicTouch at one year of follow-up, compared to treatment "or with an uncoated balloon." This new sub-analysis, which includes 597 patients with femoropopliteal disease without tissue loss, will provide key data on a cohort of great clinical interest, where the goals of revascularization are not limited to preserving the limb, but also seek sustained relief of symptoms.
"The results will be presented by Prof. Dr. Stefano Barco (Co-PI) as part of the late-breaking clinical trial program at VIVA 2026, one of the leading international meetings dedicated to peripheral vascular disease and endovascular therapy."
About the SirPAD trial
"SirPAD Trial is an academic, investigator initiated RCT comparing Sirolimus Coated Balloon (MagicTouch PTA) against uncoated balloon treatment in patients with femoropopliteal or below-the-knee disease. The trial enrolled 1,252 patients with the primary outcome published in the New England Journal of Medicine, indicating that treatment with Sirolimus Coated Balloon arm was both non-inferior and superior against uncoated balloon in terms of MALE."
About Concept Medical
"Concept Medical Group develops innovative drug-delivery technologies for coronary and peripheral vascular interventions. The company is the developer of MagicTouch PTA, the sirolimus-coated balloon evaluated in the SirPAD randomized trial."
"If you would like more information: www.conceptmedical.com"
"View original content to download multimedia:https://www.prnewswire.com/news-releases/estudio-en-viva-2026---enfermedad-arterial-periferica-eap-femoropoplitea-en-pacientes-con-claudicacion-302884645.html"